|
HS Code |
371527 |
| Chemical Name | 2-Isopropyl-4((N - Methyl)Amino)Methyl)Thiazole Dihydrochloride (Mtv - II) |
As an accredited 2-Isopropyl-4(((N-Methyl)Amino)Methyl)Thiazole Dihydrochloride (Mtv-Ii) factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | One - gram vial packaging for 2 - Isopropyl - 4((N - Methyl)Amino)Methyl)Thiazole Dihydrochloride (MTV - II). |
| Shipping | Ship 2 - Isopropyl - 4((N - Methyl)Amino)Methyl)Thiazole Dihydrochloride (MTV - II) in accordance with chemical shipping regulations. Ensure proper packaging to prevent spills, and transport it via a method suitable for hazardous chemicals. |
| Storage | Store 2 - Isopropyl - 4((N - Methyl)Amino)Methyl)Thiazole Dihydrochloride (MTV - II) in a cool, dry place away from direct sunlight. Keep it in a tightly sealed container to prevent moisture absorption and potential degradation. Avoid storing near incompatible substances. Ideal storage temperature is typically around 2 - 8°C in a refrigerator if specified for long - term stability. |
In retroviral protease inhibitor synthesis, the dihydrochloride salt of 2-isopropyl-4-(((N-methyl)amino)methyl)thiazole (Mtv-Ii) functions as a direct precursor to the 2-isopropylthiazol-4-ylmethyl amine fragment required for carbamate bond formation in ritonavir. The free base is liberated in situ by treatment with 2.5–3.0 molar equivalents of triethylamine in dichloromethane at 0 °C to 5 °C prior to coupling with (2S,3S,5S)-2,5-diamino-1,6-diphenyl-3-hydroxyhexane derivatives. Anhydrous conditions are mandatory; the batch is typically dried under vacuum (≤ 0.1 mbar) at 40 °C for 18 hours until Karl Fischer titration reads ≤ 0.15 wt% water. In commercial-scale campaigns this freebasing step is run in a 5000 L glass-lined reactor with a retreat-blade agitator operating at 90–110 rpm, and the exothermic neutralization is controlled by jacket brine circulation set to −10 °C. The amine intermediate is taken directly into the coupling stage without isolation; the chloroformate-activated (thiazol-5-yl)methyl carbamate counterpart is added dropwise over 120–150 minutes while internal temperature is held at 2 ± 2 °C. Unreacted amine is scavenged with polymer-supported isocyanate resin (1.5 eq relative to initial charge), then filtered through a 0.5 μm polypropylene bag filter under nitrogen pressure. Final ritonavir polymorph (Form I) is crystallized from ethyl acetate/n-heptane (1:4 v/v) with seeding at 38 °C. Regulatory dossiers commonly reference DMF Type II filings under 21 CFR 314.420 and the intermediate must satisfy residual solvent profiles according to USP <467> and ICH Q3C, with particular attention to dichloromethane (≤ 600 ppm) and triethylamine (≤ 320 ppm). Heavy metal compliance is verified by USP <231> or replacement methods per USP <232>/<233>, targeting ≤ 10 ppm palladium when catalytic hydrogenolysis steps are employed upstream. Stability studies under ICH Q1A(R2) confirm 24-month retest dating when the salt is double-bagged in antistatic LDPE liners inside fiber drums, stored at 2–8 °C with desiccant packs maintaining headspace RH ≤ 15 %. Primary end-product distribution is in fixed-dose antiretroviral combination tablets also containing lopinavir or darunavir, where the thiazole carbamate moiety blocks HIV-1 protease dimerization at picomolar Ki values.What Makes the N-Methylaminomethyl Substituent Indispensable in Pharmacoenhancer Architectures?Cobicistat, a CYP3A4 inhibitor devoid of antiviral activity, shares the identical 2-isopropylthiazol-4-ylmethyl methylamine core with ritonavir but routes the free amine through a distinct morpholine-acetamide side-chain conjugation. Mtv-Ii serves as the convergent building block for this bifurcated pharmacophoric design. The amine hydrochloride is first converted to its triethylamine-free base in THF at −15 °C, then acylated with 2-morpholinoacetyl chloride hydrochloride under Schotten-Baumann conditions using 10 wt% aqueous potassium carbonate as the acid sponge. The biphasic mixture is vigorously stirred in a 2000 L Hastelloy C-276 reactor equipped with a radial turbine impeller generating a tip speed of 3.8 m/s to ensure interfacial mass transport; inadequate shear results in unreacted amine partitioning into the organic layer and formation of symmetrical urea byproduct detected at LC-rt 6.8 min on a C18 column. Pilot-plant campaigns routinely set the acyl chloride charge to 1.03–1.07 eq relative to assayed amine and perform endpoint monitoring by inline ReactIR, tracking the disappearance of the isocyanate intermediate peak at 2275 cm⁻¹. The post-reaction organic phase is washed with 5 wt% citric acid to remove morpholine-related process impurities, then subjected to vacuum distillation at 50 mbar and 38 °C jacket temperature to displace THF with isopropanol ahead of crystallization. Cobicistat freebase is isolated from isopropanol/water (3:2 v/v) by cooling from 60 °C to −5 °C at a controlled ramp of 0.15 °C/min, yielding a Form A polymorph with D[v,0.9] particle size ≤ 45 μm as measured by laser diffraction (ISO 13320:2020). Quality release specifications demand enantiomeric purity ≥ 99.5 % by chiral HPLC (Chiralpak IC, hexane/ethanol/diethylamine 90/10/0.1), residual morpholine below 100 ppm (GC-FID, LOD 5 ppm), and palladium content ≤ 5 ppm by ICP-MS. Because cobicistat is co-formulated with elvitegravir, emtricitabine, and tenofovir alafenamide in a single-tablet regimen, the Mtv-Ii-derived intermediate is subject to supplier qualification audits involving ISO 9001:2015 and EXCiPACT certification schemes, with full supply-chain mapping under EU Falsified Medicines Directive (2011/62/EU). Finished pharmaceutical product stability per ICH Q1A(R2) Zone IVb conditions demonstrates 36-month shelf life for HDPE bottles with induction-sealed aluminum liners.Coordination Geometry Perturbation by a Pendant Amine DonorThe 2-isopropylthiazole core, when combined with the N-methylaminomethyl arm, constitutes a bidentate N,N-chelator capable of fine-tuning Lewis acidity at transition-metal centers. The dihydrochloride salt is neutralized with sodium methoxide in methanol, and the resulting free amine is reacted with anhydrous zinc(II) chloride or copper(II) bromide in acetonitrile under an argon atmosphere to form tetrahedral or square-planar complexes of composition [M(L)X₂]. Electronic perturbation by the isopropyl group at the thiazole 2-position increases the σ-donating character of the ring nitrogen relative to a methyl-substituted analog; comparative cyclic voltammetry in 0.1 M TBAPF₆/DMF shows an anodic shift of +115 mV for the Cu(II)/Cu(I) couple when the isopropyl variant is employed. This redox modulation has been exploited in atom-transfer radical polymerization (ATRP) catalyst screening, where the Mtv-Ii-derived CuBr complex in conjunction with ethyl α-bromoisobutyrate as initiator yields poly(methyl methacrylate) with dispersity Đ = 1.08–1.14 at 60 % conversion (GPC calibrated against PMMA standards, THF eluent). Equipment for ligand-complex preparation on a 50 kg scale uses a 200 L glass-lined cryogenic reactor capable of maintaining −30 °C during the exothermic methoxide addition; the sodium chloride precipitate is removed through a 0.2 μm cartridge filter under inert gas push. For pharmaceutical-grade metal scavenging applications, the immobilized ligand on Merrifield resin (loading 0.8–1.2 mmol/g) achieves palladium removal from API streams to ≤ 1 ppm residual Pd at a weight hourly space velocity of 4 h⁻¹, validated by USP <233> sample digestion and ICP-MS quantitation. Process safety assessments require differential scanning calorimetry (ASTM E537-20) on the neat complex to confirm no exothermic decomposition onset below 180 °C.
When a Thiazole-Isobutyl Fragment Bridges the Hinge Region in Kinase PharmacophoresThe 2-isopropylthiazol-4-ylmethyl methylamine fragment accessed from Mtv-Ii has been incorporated into Type II kinase inhibitors where the thiazole ring occupies the adenine-binding pocket and the pendant N-methylaminomethyl arm engages the adjacent phosphate-binding loop via hydrogen bonding to backbone carbonyl oxygens. In a disclosed synthesis of a selective dual BTK/EGFR inhibitor, the dihydrochloride salt is coupled to a pyrimido-pyridazinone core through a carbamate linkage using 1,1′-carbonyldiimidazole (CDI, 1.3 eq) in acetonitrile at 40 °C. The pre-activation step forms an imidazolide intermediate that is verified by the disappearance of the CDI carbonyl resonance at δ 148.2 ppm in 13C NMR and appearance of a new carbonyl signal at δ 152.5 ppm. The freebase amine (generated from Mtv-Ii with 1.05 eq of diisopropylethylamine) is added in one portion; the reaction is aged for 8 hours and quenched with 1 M HCl to destroy excess CDI. Product isolation employs ethyl acetate extraction followed by anti-solvent crystallization from MTBE/n-heptane (1:2 v/v), yielding an off-white crystalline solid with melting point 168–170 °C (DSC, 10 °C/min). Residual palladium from upstream Suzuki coupling steps is controlled to ≤ 10 ppm by treatment with SiliaMetS Thiol scavenger (0.8 wt% relative to product) during the organic extract stage. This late-stage scavenging protocol is critical because metal contamination exceeding 20 ppm has been correlated with accelerated hydrolytic degradation of the carbamate bond at 40 °C/75 % RH over 4 weeks (stressed stability screening per ICH Q1B option 2).Analytical batch records for the kinase inhibitor intermediate mandate LC-MS purity ≥ 98.0 % area at 254 nm, single impurity ≤ 0.50 %, and chiral purity of the parent inhibitor ≥ 99.0 % ee by SFC with a Chiralpak AD-H column (CO₂/methanol 70/30, 40 °C, 120 bar backpressure). The dihydrochloride starting material must show identity by FTIR matching the reference spectrum (pharmaceutical secondary standard) and chloride content 20.5–21.5 % by argentometric titration. For shipments under US FDA 21 CFR Part 11 enabled quality systems, certificates of analysis are appended with electronic signatures and audit trails.Reference standard applications constitute a parallel, lower-volume but high-value segment. Mtv-Ii certified as a pharmaceutical secondary standard (ISO 17034:2016) is supplied in amber glass vials sealed under argon with a certified purity of 99.80 ± 0.35 % (mass balance, k=2 confidence interval). The standard is characterized by quantitative NMR (¹H qNMR using internal calibrant 1,2,4,5-tetrachloro-3-nitrobenzene, traceable to NIST SRM 350b), Karl Fischer coulometry, and headspace GC-MS for residual solvents. The accompanying certificate details the uncertainty budget calculated in accordance with ISO 21748:2017 and confirms homogeneity assessed on 10 stratified units by Karl Fischer analysis showing inter-vial variance ≤ 0.02 %. Storage guidelines stipulate 2–8 °C in the unopened original container, with a stated shelf life of 24 months from certification date. Analytical laboratories sourcing this standard deploy it for system suitability tests in compendial HPLC assay methods for ritonavir oral tablets, typically injecting 10 μL of a 0.25 mg/mL solution in mobile phase and verifying resolution between the thiazole-containing peak and the adjacent process-related compound peak at RRT 1.12 with a requirement ≥ 2.0. Any single batch lot is reserved for 500–1000 individual testing operations before its certified value is revalidated against a newly prepared primary standard.
|
Competitive 2-Isopropyl-4(((N-Methyl)Amino)Methyl)Thiazole Dihydrochloride (Mtv-Ii) prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
| Parameter | Method Reference | Specification | Typical Lot Value (n=12) |
| Assay (anhydrous, HCl salt form) | USP <541> (non-aqueous) | 98.0–102.0% | 99.4% |
| Water content | USP <921>, Method Ia | ≤0.5% | 0.21% |
| Residual isopropanol | USP <467> (GC–FID) | ≤5000 ppm | 820 ppm |
| Residual MTBE | USP <467> | ≤5000 ppm | 210 ppm |
| N-methyl-2-chloroacetamide | In-house LC–MS/MS | ≤5 ppm | |
| Palladium (Pd) | USP <233> (ICP–MS) | ≤20 ppm | 4 ppm |
| Intermediate | Physical State (25 °C) | Typical Assay | Preferred Functionalization Sequence | Key Handling Concern |
| Mtv-II (dihydrochloride) | Crystalline powder | ≥98% | N-alkylation → C5 metallation | Pre-dry at 40 °C, 10 mbar for 4 h before anhydrous coupling |
| 2-Isopropyl-4-(chloromethyl)thiazole | Amber oil | 92–95% (typical) | C5 lithiation → chloride displacement | Lachrymator; requires storage under N₂ |
| 2-Isopropyl-4-(aminomethyl)thiazole (free base) | Yellow oil | 90–94% | C5 electrophilic substitution → N-protection | CO₂ absorption; rapid viscosity increase upon aging |
| Mtv-II free base (isolated) | Pale yellow oil | 95–97% | In situ generation only | Oxidizes to N-oxide under ambient light |